Core Insights - IDEAYA Biosciences is set to participate in investor relations events and has provided updated guidance on the topline data release from the Phase 2/3 OptimUM-02 trial for HLA-A2*-negative metastatic uveal melanoma [1][5] Upcoming Events - The company will host a webcast during the Bank of America Merrill Lynch Health Care Conference on May 12, 2026, featuring a fireside chat with CEO Yujiro S. Hata [2] - Another fireside chat will take place at the Stifel 2026 Targeted Oncology Virtual Forum on May 19, 2026, also featuring CEO Yujiro S. Hata [2] Company Overview - IDEAYA is focused on precision medicine in oncology, aiming to discover and develop targeted therapies for cancer [3] - The company integrates small-molecule drug discovery, structural biology, and bioinformatics to create tailored therapies aligned with genetic disease drivers [3] - IDEAYA has a pipeline that includes synthetic lethality and antibody-drug conjugates (ADCs) for solid tumor indications [3] Updated Guidance - The database lock for the OptimUM-02 trial is expected in the first half of April, with topline data analysis to follow [5]

Core Insights - IDEAYA Biosciences is set to present three clinical stage pipeline programs at the AACR Annual Meeting, showcasing potential first-in-class therapies targeting various cancer types [1][2]. Group 1: Pipeline Programs - The three highlighted programs include IDE034, a bi-specific antibody-drug conjugate targeting PTK7 and B7H3; IDE574, a dual inhibitor of lysine acetyltransferases KAT6 and KAT7; and IDE892, a PRMT5 inhibitor [1][3]. - These programs are currently undergoing Phase 1 clinical studies to assess their safety, tolerability, pharmacokinetics, and efficacy across multiple solid tumor indications, including lung, colorectal, pancreatic, breast, and prostate cancers [1][3]. Group 2: Presentation Details - The poster presentations will cover the following topics: - IDE034's enhanced antitumor activity compared to mono-specific ADCs, scheduled for April 19, 2026 [3]. - IDE574's ability to disrupt tumor lineage identity and drug tolerance, scheduled for April 21, 2026 [3]. - IDE892's selective inhibition of PRMT5, also scheduled for April 21, 2026 [3]. Group 3: Company Overview - IDEAYA Biosciences focuses on precision medicine in oncology, aiming to develop transformative therapies through a combination of small-molecule drug discovery, structural biology, and bioinformatics [4]. - The company is committed to creating targeted therapies that align with the genetic drivers of cancer, emphasizing synthetic lethality and antibody-drug conjugates [4].

Core Insights - IDEAYA Biosciences has initiated a Phase 1 clinical trial for IDE892, a potential best-in-class PRMT5 inhibitor targeting MTAP-deleted solid tumors, including non-small cell lung cancer (NSCLC) and pancreatic cancer [1] - The company plans to deprioritize combination activities with Trodelvy to focus on its proprietary MTAP-deleted and CDKN2A pipeline, aiming for a first-in-class CDKN2A development candidate nomination in H2 2026 and an IND submission in H1 2027 [1] Group 1: IDE892 Development - The first patient has been enrolled in the Phase 1 trial evaluating IDE892, which will assess safety, tolerability, pharmacokinetics, and pharmacodynamics as a monotherapy and in combination with IDE397 [1] - IDE892 exhibits approximately 1,400-fold selective binding to MTA-PRMT5 versus SAM-PRMT5 complexes and demonstrates single-digit nanomolar potency in MTAP-deleted cell lines [1] - Preclinical studies show that dual inhibition of PRMT5 and MAT2A with IDE892 and IDE397 resulted in durable tumor regressions in MTAP-deleted tumor models [1] Group 2: CDKN2A Program - IDEAYA is advancing its CDKN2A-deficiency program, targeting a first-in-class development candidate selection in H2 2026 and an IND submission in H1 2027 [1] - CDKN2A deficiency is prevalent in over 80% of pancreatic cancer cases and is often co-deleted with MTAP, creating opportunities for rational combination therapies [1] - The company has demonstrated robust monotherapy efficacy with its CDKN2A lead in multiple preclinical models, including a KRAS mutation pancreatic model [1] Group 3: Strategic Prioritization - As part of its strategic focus, IDEAYA has deprioritized clinical combination activities with Trodelvy and will conclude enrollment in ongoing Phase 1/2 trials with Gilead [1] - The company may explore additional combinations between IDE397 and other TOP1 payload ADCs, including IDE034, in the context of MTAP-deleted cancers [1] - MTAP deletion occurs in 15-20% of NSCLC, up to 40% of pancreatic cancer, and approximately 15% of all solid tumors, highlighting the unmet need for targeted therapies [1]

Core Insights - IDEAYA Biosciences, Inc. is recognized as one of the 10 Fastest Growing NASDAQ Stocks to Buy [1] Group 1: Clinical Developments - On February 25, 2026, IDEAYA announced the enrollment of the first patient in its Phase 1 trial for IDE034, a bispecific ADC targeting PTK7/B7H3, with a focus on safety, tolerability, and pharmacokinetics [2] - The company plans to explore combinations of IDE034 with agents targeting the DNA damage response pathway, including its proprietary PARG inhibitor IDE161 [2] - The initiation of dosing for the first patient triggers a $5 million milestone payment from IDEAYA to Biocytogen as per their licensing agreement [2] Group 2: Leadership Changes - On February 23, 2026, IDEAYA appointed Theodora Ross as the chief development officer to lead early clinical development for the oncology pipeline and guide long-term R&D strategy [3] - Ross previously held the position of VP and head of early oncology R&D at AbbVie [3] Group 3: Financial Performance - IDEAYA reported Q4 revenue of $10.88 million, significantly exceeding consensus estimates of $5.95 million [4] - The revenue reflects collaboration performance obligations related to research and development services under the Servier exclusive license agreement for darovasertib [4] - President and CEO Yujiro Hata highlighted strong clinical execution, pipeline expansion, and commercial readiness activities, including the completion of enrollment of 437 patients in the OptimUM-02 Phase 2/3 trial [4]

Core Insights - High growth stocks are gaining attention, with earnings momentum being a key factor for investment decisions, as noted by J.P. Morgan Asset Management, which highlights four consecutive quarters of double-digit earnings growth [2] - Vanguard's outlook suggests that U.S. technology stocks may sustain their momentum due to ongoing investment and anticipated earnings growth, while also cautioning about increasing risks [3] - The focus is on fast-growing companies with sustained revenue acceleration and structural drivers, rather than those benefiting solely from earnings multiple expansion [4] Company Analysis IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - IDEAYA announced the enrollment of the first patient in its Phase 1 trial for IDE034, triggering a $5 million milestone payment [9] - The company reported Q4 revenue of $10.88 million, significantly exceeding consensus estimates of $5.95 million, and highlighted strong clinical execution and pipeline expansion [11] - IDEAYA focuses on precision medicine in oncology, developing targeted therapeutics based on molecular diagnostics [12] Eos Energy Enterprises, Inc. (NASDAQ:EOSE) - Eos Energy faced mixed analyst actions, with Stifel lowering its price target to $12 while maintaining a Buy rating, and Guggenheim downgrading to Neutral [13] - The company reported Q4 EPS of (84 cents), below consensus estimates of (24 cents), and Q4 revenue of $58 million, which was also below the $93.69 million consensus [14] - Eos Energy aims to improve operational efficiency and convert backlog into revenue, with a focus on disciplined scaling and margin improvement [14][15]

Core Insights - Biocytogen Pharmaceuticals has announced that its partner IDEAYA Biosciences has initiated the first patient dosing in a Phase 1 clinical trial for IDE034, a bispecific antibody-drug conjugate targeting B7H3/PTK7 [1] Company Summary - Biocytogen Pharmaceuticals is a global biotechnology company focused on the research and development of novel antibody-based drugs utilizing innovative technologies [1] - IDEAYA Biosciences, a partner of Biocytogen, is conducting the clinical trial for IDE034, which is currently in the dose-escalation and expansion phase [1]

Core Insights - IDEAYA Biosciences has initiated a Phase 1 trial for IDE034, a bispecific TOP1 ADC targeting B7H3/PTK7, which is co-expressed in 30-40% of various solid tumors, including lung, breast, ovarian, and colorectal cancers [1] - The trial aims to evaluate the safety, tolerability, and pharmacokinetics of IDE034, both as a monotherapy and in combination with the proprietary PARG inhibitor, IDE161 [1] - The first patient dosing triggers a $5 million milestone payment to Biocytogen, highlighting the collaboration between the two companies [1] Company Overview - IDEAYA Biosciences is focused on precision medicine in oncology, aiming to develop transformative therapies for cancer through a combination of small-molecule drug discovery, structural biology, and bioinformatics [1] - The company has a robust pipeline of product candidates, particularly in synthetic lethality and antibody-drug conjugates (ADCs), targeting molecularly defined solid tumor indications [1] - IDE034 represents the second proprietary TOP1 ADC from IDEAYA, following IDE849, which is currently in Phase 1 for small cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC) [1] Clinical Development - The Phase 1 trial will assess IDE034's potential as a first-in-class therapy, with preclinical models showing promising efficacy and synergy when combined with IDE161 [1] - The design of IDE034 allows for internalization only when both target antigens are present on the same tumor cell, potentially enhancing selectivity and tolerability compared to traditional antibody formats [1] - IDEAYA estimates minimal dual antigen expression in normal tissues, which may further improve the therapeutic profile of IDE034 [1]

Core Insights - IDEAYA Biosciences is a leading precision medicine oncology company with a diversified portfolio of 9 clinical programs [1] Group 1: Clinical Programs - The most advanced program is Darovasertib, currently in two Phase III randomized studies for first-line metastatic uveal melanoma and neoadjuvant indications, with a third Phase III study expected to launch in the current half [2] - The primary endpoint for the first-line metastatic melanoma study is median progression-free survival, which is a key focus for the company [3] Group 2: Pipeline and Assets - IDEAYA has a portfolio of assets in the antibody-drug conjugate (ADC) space, with significant attention on DLL3 TOP1 ADC, IDE849, which is expected to provide a clinical data update by the end of the year [4] - The company also has a deep pipeline related to MTAP-deletion, indicating ongoing research and development efforts in this area [5]

Summary of IDEAYA Biosciences Update - February 23, 2026 Company Overview - **Company**: IDEAYA Biosciences (NasdaqGS:IDYA) - **Industry**: Precision medicine oncology - **Programs**: 9 clinical programs, with a focus on darovasertib in phase 3 studies for metastatic uveal melanoma [1][3] Key Points and Arguments Clinical Programs - **Darovasertib**: - Currently in two phase 3 randomized studies for first-line metastatic uveal melanoma and neoadjuvant indications [1] - Upcoming guidance on top-line results expected by the end of March 2026, focusing on median progression-free survival (PFS) as the primary endpoint [4][5] - Reported a solid 7-month PFS in previous presentations, with a follow-up of approximately 2 years [5][11] - **DLL3 Topo ADC (IDE-849)**: - Anticipated clinical data update by the end of 2026, with potential to be a best-in-class asset [2] - **MTAP Deletion Programs**: - Two clinical assets (PRMT5 and MAT2A) with opportunities for both monotherapy and combination therapy [2] - **KAT6/7 (IDE-574)**: - Entered phase 1, targeting a large patient population including breast and colorectal cancer [3] Trial Design and Expectations - **Trial Design**: - Simple randomized phase 3 comparison of darovasertib-crizotinib combination versus standard of care (checkpoint inhibitors) [15] - Control arm expected to show PFS of approximately 2-3 months based on meta-analyses [10][11] - **PFS and OS Analysis**: - The treatment arm is expected to outperform the control arm, with a significant buffer for achieving statistical significance [11][12] - Overall survival (OS) data shows a promising 21-month survival rate, with expectations for positive outcomes in the ongoing study [11][12][128] Patient Population and Disease Characteristics - **Uveal Melanoma**: - Majority of patients (over 90%) present with liver metastases, making liver-directed therapies critical [167][176] - Approximately one-third of patients have elevated LDH levels, indicating disease severity [180][181] Regulatory and Future Plans - **FDA Submission**: - Plans to file for approval based on PFS data, with OS data to be presented during the review process [136][186] - Anticipated timeline for filing and review is approximately 12 months, targeting first half of 2027 for potential approval [187] - **NCCN Guidelines**: - Plans to present data to the NCCN panel to support treatment inclusion for both HLA-A2 negative and positive patients [189] Neoadjuvant Study (OptimUM-09) - **OptimUM-09 Study**: - Focused on neoadjuvant treatment with promising results in tumor shrinkage and vision preservation [191] - Aims to change the treatment paradigm from surgical interventions to pharmacological management [195] Additional Important Information - **Safety Profile**: - Expected to be comparable to previous studies, with a focus on managing adverse events effectively [155] - Investigators are becoming more adept at handling treatment-related toxicities, which may lead to lower discontinuation rates [156] - **Data Review Process**: - The independent review of PFS is ongoing, with a target completion by the end of March 2026 [144] This summary encapsulates the key points from the IDEAYA Biosciences update, highlighting the company's focus on innovative oncology treatments, ongoing clinical trials, and strategic regulatory plans.

Core Insights - IDEAYA Biosciences has appointed Dr. Theodora (Theo) Ross as Chief Development Officer to lead early clinical development and guide long-term R&D strategy [1] - Dr. Ross has over 30 years of oncology experience, previously serving as Vice President at AbbVie, where she advanced five early clinical stage programs and was involved in a $10 billion acquisition [1] - The company focuses on precision medicine and aims to develop transformative therapies for cancer, with a pipeline centered on synthetic lethality and antibody-drug conjugates [1] Company Overview - IDEAYA Biosciences is a precision medicine oncology company dedicated to discovering, developing, and commercializing targeted therapies for cancer [1] - The company integrates expertise in small-molecule drug discovery, structural biology, and bioinformatics to develop tailored therapies aligned with genetic disease drivers [1] - IDEAYA's mission is to create selective, effective, and personalized oncology therapies to improve clinical outcomes for cancer patients [1] Leadership Appointment - Dr. Ross's role will be crucial in advancing IDEAYA's clinical development plans and supporting the company's growth [1] - She expressed excitement about joining IDEAYA and emphasized the importance of scientific rigor and focus in oncology [1] - Dr. Ross's background includes leadership roles in global pharma companies and significant academic experience in cancer genetics [1]